AU2020261234B2 - Modulators of the integrated stress response pathway - Google Patents

Modulators of the integrated stress response pathway

Info

Publication number
AU2020261234B2
AU2020261234B2 AU2020261234A AU2020261234A AU2020261234B2 AU 2020261234 B2 AU2020261234 B2 AU 2020261234B2 AU 2020261234 A AU2020261234 A AU 2020261234A AU 2020261234 A AU2020261234 A AU 2020261234A AU 2020261234 B2 AU2020261234 B2 AU 2020261234B2
Authority
AU
Australia
Prior art keywords
oxadiazol
chloro
acetamide
piperidin
fluorophenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020261234A
Other languages
English (en)
Other versions
AU2020261234A1 (en
Inventor
Holly ATTON
Christopher John Brown
James Lindsay Carr
Serge CONVERS-REIGNIER
Michael Corr
Marissa FLOWER
Christopher Francis Palmer
Irena Doly REBOULE
Mohamad SABBAH
Scott Sadler
Jonathan Shine
Daryl Simon Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec International GmbH
Original Assignee
Evotec International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec International GmbH filed Critical Evotec International GmbH
Publication of AU2020261234A1 publication Critical patent/AU2020261234A1/en
Application granted granted Critical
Publication of AU2020261234B2 publication Critical patent/AU2020261234B2/en
Priority to AU2026203062A priority Critical patent/AU2026203062A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of El Displays (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Semiconductor Integrated Circuits (AREA)
AU2020261234A 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway Active AU2020261234B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026203062A AU2026203062A1 (en) 2019-04-23 2026-04-23 Modulators of the integrated stress response pathway

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19170504.5 2019-04-23
EP19170504 2019-04-23
EP19216875.5 2019-12-17
EP19216875 2019-12-17
PCT/EP2020/061150 WO2020216766A1 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026203062A Division AU2026203062A1 (en) 2019-04-23 2026-04-23 Modulators of the integrated stress response pathway

Publications (2)

Publication Number Publication Date
AU2020261234A1 AU2020261234A1 (en) 2021-11-11
AU2020261234B2 true AU2020261234B2 (en) 2026-02-05

Family

ID=70289816

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020261234A Active AU2020261234B2 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway
AU2026203062A Pending AU2026203062A1 (en) 2019-04-23 2026-04-23 Modulators of the integrated stress response pathway

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026203062A Pending AU2026203062A1 (en) 2019-04-23 2026-04-23 Modulators of the integrated stress response pathway

Country Status (15)

Country Link
US (2) US12258338B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959198A1 (cg-RX-API-DMAC7.html)
JP (2) JP7590343B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004105A (cg-RX-API-DMAC7.html)
CN (1) CN113993850B (cg-RX-API-DMAC7.html)
AU (2) AU2020261234B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020402A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002772A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014292A2 (cg-RX-API-DMAC7.html)
IL (1) IL287379B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021012903A (cg-RX-API-DMAC7.html)
PE (1) PE20220961A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111119PA (cg-RX-API-DMAC7.html)
WO (1) WO2020216766A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108151B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CR20210426A (es) * 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
MX2021012904A (es) * 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
MX2023004677A (es) * 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
WO2022212902A1 (en) * 2021-04-02 2022-10-06 Altos Labs, Inc. Modulators of integrated stress response pathway
AU2023384649A1 (en) 2022-11-21 2025-05-22 Shenzhen Zhongge Biological Technology Co., Ltd. Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof
CN116854623B (zh) * 2023-07-11 2025-08-05 齐鲁安替制药有限公司 一种阿维巴坦中间体的制备方法
CN121986087A (zh) 2023-10-13 2026-05-05 国立研究开发法人国立精神·神经医疗研究中心 神经保护剂
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017212425A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2017212423A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemcical compounds
WO2019046779A1 (en) * 2017-09-01 2019-03-07 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
WO2019090081A1 (en) * 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639761B1 (en) 1999-12-02 2003-10-28 Seagate Technology Llc Micro-actuator damping and humidity protection
AU2001233044A1 (en) * 2000-01-28 2001-08-07 Akkadix Corporation Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles
US7915433B2 (en) 2004-04-16 2011-03-29 Wayne State University Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives
WO2014144952A2 (en) * 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
WO2017046739A1 (en) 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI920577B (zh) 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CN110730777A (zh) 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
DE102017213834A1 (de) * 2017-08-08 2019-02-14 Robert Bosch Gmbh Sende-/Empfangseinrichtung für ein Bussystem und Verfahren zur Reduzierung einer Schwingneigung beim Übergang zwischen unterschiedlichen Bitzuständen
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
BR112020008825A2 (pt) 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
MX2020004537A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía integrada del estrés.
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
EP3704125B1 (en) 2017-11-02 2026-03-11 Calico Life Sciences LLC Modulators of the integrated stress pathway
MX2020004538A (es) 2017-11-02 2020-09-18 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017212425A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2017212423A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemcical compounds
WO2019046779A1 (en) * 2017-09-01 2019-03-07 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
WO2019090081A1 (en) * 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway

Also Published As

Publication number Publication date
JP2022530049A (ja) 2022-06-27
PE20220961A1 (es) 2022-06-10
AU2026203062A1 (en) 2026-05-07
WO2020216766A1 (en) 2020-10-29
SG11202111119PA (en) 2021-11-29
JP2025024086A (ja) 2025-02-19
IL287379B1 (en) 2025-07-01
US20220227747A1 (en) 2022-07-21
IL287379B2 (en) 2025-11-01
US12258338B2 (en) 2025-03-25
JP7878648B2 (ja) 2026-06-23
CA3137213A1 (en) 2020-10-29
BR112021020402A2 (pt) 2021-12-07
US20250188071A1 (en) 2025-06-12
CO2021014292A2 (es) 2022-04-29
CN113993850A (zh) 2022-01-28
IL287379A (en) 2021-12-01
AU2020261234A1 (en) 2021-11-11
MX2024015479A (es) 2025-02-10
ZA202108151B (en) 2026-04-29
EP3959198A1 (en) 2022-03-02
MX2021012903A (es) 2022-01-18
KR20220004105A (ko) 2022-01-11
CL2021002772A1 (es) 2022-07-29
JP7590343B2 (ja) 2024-11-26
CN113993850B (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
JP7590343B2 (ja) 統合ストレス応答経路のモジュレーター
JP7699595B2 (ja) 統合的ストレス応答経路の調節因子
AU2021236284B2 (en) Modulators of the integrated stress response pathway
AU2021363616B2 (en) Modulators of the integrated stress response pathway
AU2021367147B2 (en) Modulators of the integrated stress response pathway
EP4232154B1 (en) Modulators of the integrated stress response pathway
HK40068295A (en) Modulators of the integrated stress response pathway
EA046988B1 (ru) Модуляторы пути интегрированной реакции на стресс

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)